Steve Davis: Thanks, Brendan. I will take the second part of the question. I think in terms of risk to an approval, I will start just repeating what we said before and that is, we just don’t comment on back and forth with the agency and we are in under review, it’s just always been our standing policy. Having said that, as we have said, we are eager to get to March 12. The FDA — we are very happy with the level of engagement we have had with FDA, and as noted a second ago, they just confirmed this recently as this morning that Billy Dunn’s departure will not have any impact and so we are eager to get to March 12. Everything appears to be on track at this point.
Unidentified Analyst: Thanks so much.
Operator: Thank you. One moment for our next question. Our next question comes from the line of Ami Fadia from Needham.
Unidentified Analyst: Hi. Good afternoon. This is Will Cindy on for Ami. Thanks for taking my question. Maybe just a two-parter on PDP. First, could you comment on kind of the longer term trajectory of the franchise and whether we could see a reacceleration of growth in 2024? And then, second, does your guidance range in 2023 assume kind of improving inpatient volumes or whatnot to take place sometime this year? Thank you.
Steve Davis: I will briefly answer first question. We don’t guide beyond the current year. So as we progress this year, we will continue to offer as much color as we can feels appropriate. Brendan, do you want to take the second part of the question?
Brendan Teehan: Sure and thanks for the question. When we look at 2023, I think, we described in our prepared remarks where we think things are. We do see some improvement in the long-term care channel. We will certainly look to continue to capitalize on that. In the in-office channel, we are focused on market share and new patient starts. You see that as evidenced by the use of the real-world evidence studies that help us differentiate NUPLAZID further from off-label atypical antipsychotics that preceded us. So in terms of market dynamics, we are operating in that market dynamic and I believe our guidance reflects that. There are two areas where we could see catalysts for growth. The first is, if in addition, to in-office visits being the preferred route for patients to see their clinicians, which we know is the case, we just need to see a frequency there increase, because frequency is going to get those patients back in front of a doctor who can see the signs and symptoms of Parkinson’s disease psychosis and treated.
We are confident in the story for NUPLAZID in that environment. We just want more opportunities for a patient to be identified. The second, which could catalyze growth is, the real-world evidence data in the form of the Mosholder Study and the Lincoln Study. The Mosholder Study was really a fourth quarter introduction and the Lincoln Study article really didn’t come out until late December. So it’s really early days in the in-office environment to be describing that. I will say anecdotally that the audience has found the information interesting, compelling and very much patient focused. So we look forward to talking about that further as the year progresses, again, early days, but that’s kind of the market dynamic we are operating in.
Unidentified Analyst: Great. Thank you.
Operator: Thank you. One moment for our next question. Pardon me, one moment for our next question. Our next question comes from the line of Jay Olson from Oppenheimer.
Jay Olson: Oh! Hey. Thanks for the ACADIAN’S for taking the question and congrats to Dr. Doug Williamson on joining ACADIA. I was wondering if you could talk about his vision for the future of R&D and the pipeline at ACADIA and are there any gaps in the pipeline that you would like to know? Thank you.
